294 related articles for article (PubMed ID: 23772024)
21. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
Front Immunol; 2021; 12():676662. PubMed ID: 34489931
[TBL] [Abstract][Full Text] [Related]
22. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
23. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation.
Deban L; Jarva H; Lehtinen MJ; Bottazzi B; Bastone A; Doni A; Jokiranta TS; Mantovani A; Meri S
J Immunol; 2008 Dec; 181(12):8433-40. PubMed ID: 19050261
[TBL] [Abstract][Full Text] [Related]
24. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
25. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants.
Perkins SJ; Nan R; Li K; Khan S; Miller A
Immunobiology; 2012 Feb; 217(2):281-97. PubMed ID: 22137027
[TBL] [Abstract][Full Text] [Related]
26. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator.
Nozal P; Garrido S; Alba-Domínguez M; Espinosa L; Peña A; Córdoba SR; Sánchez-Corral P; López-Trascasa M
Mol Immunol; 2014 Apr; 58(2):194-200. PubMed ID: 24378252
[TBL] [Abstract][Full Text] [Related]
27. Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps.
Schneider AE; Sándor N; Kárpáti É; Józsi M
Mol Immunol; 2016 Apr; 72():37-48. PubMed ID: 26938503
[TBL] [Abstract][Full Text] [Related]
28. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H.
Hellwage J; Jokiranta TS; Friese MA; Wolk TU; Kampen E; Zipfel PF; Meri S
J Immunol; 2002 Dec; 169(12):6935-44. PubMed ID: 12471127
[TBL] [Abstract][Full Text] [Related]
29. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
Roumenina LT; Roquigny R; Blanc C; Poulain N; Ngo S; Dragon-Durey MA; Frémeaux-Bacchi V
Methods Mol Biol; 2014; 1100():237-47. PubMed ID: 24218264
[TBL] [Abstract][Full Text] [Related]
30. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations.
Okemefuna AI; Nan R; Miller A; Gor J; Perkins SJ
J Biol Chem; 2010 Jan; 285(2):1053-65. PubMed ID: 19850925
[TBL] [Abstract][Full Text] [Related]
31. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
32. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.
Morgan HP; Jiang J; Herbert AP; Kavanagh D; Uhrin D; Barlow PN; Hannan JP
Acta Crystallogr D Biol Crystallogr; 2011 Jul; 67(Pt 7):593-600. PubMed ID: 21697597
[TBL] [Abstract][Full Text] [Related]
33. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
34. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H.
Mihlan M; Stippa S; Józsi M; Zipfel PF
Cell Death Differ; 2009 Dec; 16(12):1630-40. PubMed ID: 19680263
[TBL] [Abstract][Full Text] [Related]
35. Interactions of the humoral pattern recognition molecule PTX3 with the complement system.
Doni A; Garlanda C; Bottazzi B; Meri S; Garred P; Mantovani A
Immunobiology; 2012 Nov; 217(11):1122-8. PubMed ID: 22964239
[TBL] [Abstract][Full Text] [Related]
36. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
37. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces.
Ferreira VP; Herbert AP; Hocking HG; Barlow PN; Pangburn MK
J Immunol; 2006 Nov; 177(9):6308-16. PubMed ID: 17056561
[TBL] [Abstract][Full Text] [Related]
38. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
[TBL] [Abstract][Full Text] [Related]
39. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
[TBL] [Abstract][Full Text] [Related]
40. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11.
Jarva H; Jokiranta TS; Hellwage J; Zipfel PF; Meri S
J Immunol; 1999 Oct; 163(7):3957-62. PubMed ID: 10490997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
